Table 1.
Baseline characteristics for 244,597 patients with newly initiated NOAC treatment during 2008–2017 in Swedish outpatient care. Values are given as n (%) or mean (± SD)
| NOAC n = 244,597 |
No interaction n = 122,476 |
Pharmacodynamic effect n = 116,499 |
CYP3A4 and/or P-gp inhibitor n = 8927 |
CYP3A4 and/or P-gp inducer n = 3314 |
|
|---|---|---|---|---|---|
| NOAC | |||||
| Apixaban (%) | 148,108 (61) | 74,808 (61) | 69,564 (60) | 5841 (65) | 2136 (64) |
| Rivaroxaban (%) | 59,276 (24) | 29,505 (24) | 28,597 (25) | 1894 (21) | 783 (24) |
| Dabigatran (%) | 35,617 (15) | 17,524 (14) | 17,475 (15) | 984 (11) | 375 (11) |
| Edoxaban (%) | 1596 (< 1) | 639 (< 1) | 863 (< 1) | 208 (2) | 20 (< 1) |
| Interacting drug groups | |||||
| Pharmacodynamic effect (%) | 116,499 (48) | 0 (0) | 116,499 (100) | 4596 (51) | 1974 (60) |
| CYP3A4 and/or P-gp inhibitor (%) | 8927 (4) | 0 (0) | 4596 (4) | 8927 (100) | 126 (4) |
| CYP3A4 and/or P-gp inducer (%) | 3314 (1) | 0 (0) | 1974 (2) | 126 (1) | 3314 (100) |
| Age and sex | |||||
| Age, mean (SD) | 72.1 (12.9) | 71.1 (13.3) | 73.2 (12.4) | 72.4 (11.4) | 71.9 (12.3) |
| Age < 65 years (%) | 56,057 (23) | 30,948 (25) | 23,666 (20) | 1938 (22) | 753 (23) |
| Age 65–74 years (%) | 76,467 (31) | 39,263 (32) | 35,402 (30) | 2959 (33) | 1040 (31) |
| Age 75–79 years (%) | 39,560 (16) | 18,948 (15) | 19,678 (17) | 1570 (18) | 595 (18) |
| Age 80+ years (%) | 72,513 (30) | 33,317 (27) | 37,753 (32) | 2460 (28) | 926 (28) |
| Female (%) | 114,740 (47) | 56,811 (46) | 55,624 (48) | 3582 (40) | 1490 (45) |
| Cardiovascular morbidity | |||||
| CHA2DS2VASc, mean (SD) | 2.9 (1.9) | 2.6 (1.8) | 3.4 (2) | 3.1 (1.8) | 3.5 (2) |
| Ischemic stroke/stroke unspecified/TIA (%) | 35,049 (14) | 11,472 (9) | 22,859 (20) | 1140 (13) | 1085 (33) |
| Ischemic stroke (%) | 23,182 (9) | 7688 (6) | 14,997 (13) | 738 (8) | 865 (26) |
| Venous thrombosis (%) | 21,066 (9) | 9907 (8) | 10,689 (9) | 775 (9) | 488 (15) |
| Vascular disease (%) | 52,831 (22) | 13,805 (11) | 37,988 (33) | 2795 (31) | 830 (25) |
| Any severe bleed (%) | 21,045 (9) | 9015 (7) | 11,411 (10) | 1013 (11) | 510 (15) |
| Gastrointestinal bleeding (%) | 7435 (3) | 3148 (3) | 4087 (4) | 352 (4) | 148 (4) |
| Hemorrhagic stroke (%) | 1335 (< 1) | 565 (< 1) | 716 (< 1) | 39 (< 1) | 105 (3) |
| Heart failure (%) | 33,619 (14) | 14,095 (12) | 18,558 (16) | 1718 (19) | 558 (17) |
| Hypertension (%) | 113,875 (47) | 47,977 (39) | 63,059 (54) | 5132 (57) | 1810 (55) |
| Other comorbidity | |||||
| Cancer (%) | 38,589 (16) | 16,505 (13) | 20,372 (17) | 3024 (34) | 952 (29) |
| Anemia (%) | 4956 (2) | 1930 (2) | 2881 (2) | 253 (3) | 138 (4) |
| COPD/emphysema (%) | 14,138 (6) | 5877 (5) | 7852 (7) | 739 (8) | 249 (8) |
| Diabetes (%) | 32,235 (13) | 12,285 (10) | 19,249 (17) | 1405 (16) | 532 (16) |
| Liver disease (%) | 2521 (1) | 1175 (< 1) | 1263 (1) | 141 (2) | 65 (2) |
| Renal disease (%) | 7958 (3) | 3028 (2) | 4630 (4) | 574 (6) | 175 (5) |
| Dementia (%) | 5411 (2) | 1993 (2) | 3310 (3) | 139 (2) | 176 (5) |
| Obesity (%) | 2200 (< 1) | 892 (< 1) | 1246 (1) | 130 (1) | 42 (1) |
| Alcohol abuse (%) | 1536 (< 1) | 723 (< 1) | 763 (< 1) | 55 (< 1) | 57 (2) |
| Frequent falls (> 2 registrations) (%) | 3271 (1) | 1572 (1) | 1630 (1) | 116 (1) | 72 (2) |
Comorbidities indicate current or relevant previous diagnoses at baseline